Nothing Special   »   [go: up one dir, main page]

MX2024000321A - Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno. - Google Patents

Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno.

Info

Publication number
MX2024000321A
MX2024000321A MX2024000321A MX2024000321A MX2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A MX 2024000321 A MX2024000321 A MX 2024000321A
Authority
MX
Mexico
Prior art keywords
antigen
antibodies
utilization
antibody responses
epitopes
Prior art date
Application number
MX2024000321A
Other languages
English (en)
Inventor
Andrew Murphy
Christos Kyratsous
Alina Baum
Christopher Petro
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024000321A publication Critical patent/MX2024000321A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen métodos y composiciones para dirigir una respuesta de anticuerpos en un sujeto lejos de uno o más primeros epítopos de un antígeno (por ejemplo, epítopos inmunodominantes de un antígeno de vacuna) y hacia uno o más segundos epítopos del antígeno mediante la administración de uno o más anticuerpos que se dirigen a uno o más primeros epítopos del antígeno.
MX2024000321A 2021-07-05 2022-07-01 Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno. MX2024000321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163218486P 2021-07-05 2021-07-05
PCT/US2022/035968 WO2023283134A1 (en) 2021-07-05 2022-07-01 Utilization of antibodies to shape antibody responses to an antigen

Publications (1)

Publication Number Publication Date
MX2024000321A true MX2024000321A (es) 2024-01-25

Family

ID=82839285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000321A MX2024000321A (es) 2021-07-05 2022-07-01 Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno.

Country Status (10)

Country Link
US (1) US20240316169A1 (es)
EP (1) EP4367134A1 (es)
JP (1) JP2024527344A (es)
KR (1) KR20240042267A (es)
CN (1) CN118076631A (es)
AU (1) AU2022307659A1 (es)
CA (1) CA3226042A1 (es)
IL (1) IL309730A (es)
MX (1) MX2024000321A (es)
WO (1) WO2023283134A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789A (en) 1848-09-19 Improvement in fountain-pen holders and nibs
US166A (en) 1837-04-17 Standing press
US5071A (en) 1847-04-17 George page
US743A (en) 1838-05-17 Improvement in plows
US5932A (en) 1848-11-21 brown
US419A (en) 1837-10-06 Machine fob boring and mortising wheel-hubs and other articles
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993001282A1 (en) 1991-07-01 1993-01-21 Berlex Laboratories, Inc. Novel mutagenesis methods and compositions
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0906420A1 (en) 1996-06-07 1999-04-07 Massachusetts Institute Of Technology Programmed sequential mutagenesis
US5780270A (en) 1996-07-17 1998-07-14 Promega Corporation Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2433138C2 (ru) 2006-06-02 2011-11-10 Ридженерон Фармасьютикалз, Инк. Антитела высокой аффинности к il-6-рецептору человека
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US10752698B2 (en) 2014-11-14 2020-08-25 Regeneron Pharmaceuticals, Inc. Method for generating high affinity antibodies
CA3192925A1 (en) 2020-04-02 2021-03-11 Regeneron Pharamaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
IL309730A (en) 2024-02-01
EP4367134A1 (en) 2024-05-15
WO2023283134A1 (en) 2023-01-12
KR20240042267A (ko) 2024-04-01
JP2024527344A (ja) 2024-07-24
CN118076631A (zh) 2024-05-24
AU2022307659A1 (en) 2024-01-25
US20240316169A1 (en) 2024-09-26
CA3226042A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
Tan et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Cromer et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
NO20072253L (no) Forbedrede vaksiner
SA519401072B1 (ar) Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها
AU2019293244A8 (en) Personalized cancer vaccine epitope selection
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
MX350230B (es) Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.
AR075851A1 (es) Vacunas anti-cancer dirigidas contra celulas presentadoras de antigenos
NZ747262A (en) Cancer immunotherapy by immune activation or immune modulation via globo series antigens
MY155377A (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
PH12020552181A1 (en) Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
IN2012DN02368A (es)
MX363307B (es) Plataformas para suministro de antigenos.
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
Gaspar et al. Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
PH12021552853A1 (en) Antibody drug conjugates
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
Copland et al. Bacillus Calmette-Guerin induces PD-L1 expression on antigen-presenting cells via autocrine and paracrine interleukin-STAT3 circuits
WO2018182983A9 (en) NOROVIRUS PARTICLE S VACCINES AND METHODS OF MAKING AND USING SAME
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
Motozono et al. The SARS-CoV-2 Omicron BA. 1 spike G446S mutation potentiates antiviral T-cell recognition
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека